Long-term results of placental blood allografting using reduced-intensity conditioning: multicenter experience in a developing country

Ruíz-Delgado, Guillermo J.; Mancı́as-Guerra, Consuelo; Macías-Gallardo, Julio; González-Llano, Óscar; Hernández-Arizpe, Ana; Rodríguez-Romo, Laura; Martínez-Cabriales, Sylvia Aidé; Gómez‐Almaguer, David; Ruíz‐Argüelles, Guillermo J.

doi:10.1179/102453311x12953015767572

Cited by 7 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reduced-intensity conditioning (RIC) transplantation was developed to reduce the toxicity of conditioning regimens, decrease the incidence of GVHD, and preserve a curative antitumor effect corresponding to allo-HSCT [27][28][29]. To further optimize the outcome of RIC transplantation for acute leukemia, in 2007, 5 years ago our transplantation center designed an RIC regimen we named FBA consisting of fludarabine, cytosine arabinoside, and busulfan.…”

Section: Conditioning Regimen and Gvhd Prophylaxismentioning

confidence: 99%

Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia, Even with a Higher Leukemia Burden

Zhang

Yang

Song

et al. 2013

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

The prognosis of patients with refractory/relapsed acute myelogenous leukemia (rAML) is poor. Recent studies have shown that more transplant centers are choosing allogeneic peripheral blood stem cell transplantation (allo-PBSCT) for recipients, even with a higher leukemia burden. The purpose of the present study is to evaluate the outcome of rAML patients undergoing allo-PBSCT and to determine whether the disease status can predict the post-transplantation survival. The outcome of 58 patients (median age, 34 years; range, 14 to 52) with rAML who underwent allo-PBSCT in our institution from January 2000 until September 2011 was retrospectively studied. Thirty-three patients had complete remission (CR) before PBSCT, whereas 25 patients had no remission. Donors were matched related (31 patients) and unrelated (27 patients). Reducedintensity conditioning was used for 18 patients with rAML, and myeloablative conditioning was used for others. Sixty-six consecutive non-rAML patients (median age, 33 years; range, 15 to 51) who received an allo-PBSCT at the same period were used as a control. Full donor-type engraftment was achieved in all patients. After a median follow-up of 61 months, the 5-year overall survival of rAML patients was 54.21% AE 7.06%, which was lower than non-rAML patients (71.82% AE 6.4%, P ¼ .0386). However, the 5-year event-free survival for rAML and non-rAML patients had no statistical significance (53.54% AE 6.87% versus 62.07% AE 6.78%, P ¼ .2626). The 5-year overall survival between rAML patients who had CR and no remission before PBSCT was 56.06% AE 9.2% and 51.85% AE 10.83%, respectively (P ¼ .6408). These data demonstrate that allo-PBSCT is a promising and safe choice for the treatment of rAML, and the results were partially due to the rapid tapering of immunosuppressants in the early stage after PBSCT and prophylactic donor lymphocyte infusion. Meanwhile, the patients who did not achieve CR before PBSCT could also benefit from allo-PBSCT. Ó 2013 American Society for Blood and Marrow Transplantation. METHODS Patient Characteristics Patients were included in the rAML group if they fulfilled the following criteria: primary failure to achieve a CR after two cycles of standard induction therapy, relapse after a first CR of fewer than 6 months, second or Financial disclosure: See Acknowledgments on page 659.

show abstract

Section: Conditioning Regimen and Gvhd Prophylaxismentioning

confidence: 99%

Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia, Even with a Higher Leukemia Burden

Zhang

Yang

Song

et al. 2013

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

show abstract

“…With the experience of reduced-intensity conditioning to graft allogeneic stem cells, we have also conducted procedures with placental blood [7] and haploidentical peripheral blood stem cells [8], on an outpatient basis and at diminished costs. Table 1 shows some salient data figures of the long-term overall survival of more than 700 patients given stem cell grafts employing these simplified SCT methods.…”

Section: Tablementioning

confidence: 99%

Stem Cell Transplantation Procedures Are Becoming Affordable for Individuals Living in Developing (Middle-Income) Countries

Ruíz‐Argüelles

2015

Acta Haematol

View full text Add to dashboard Cite

Recent Patents on Perinatal Stem Cells

Yawno¹,

Wallace²,

Lim³

2014

Perinatal Stem Cells

View full text Add to dashboard Cite

Long-term results of placental blood allografting using reduced-intensity conditioning: multicenter experience in a developing country

Abstract: The low engraftment rate should be improved by selecting better cord blood units; additional studies are needed to define if non-myeloablative conditioning is preferable over conventional conditioning.

Cited by 7 publications

References 18 publications

Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia, Even with a Higher Leukemia Burden

Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia, Even with a Higher Leukemia Burden

Stem Cell Transplantation Procedures Are Becoming Affordable for Individuals Living in Developing (Middle-Income) Countries

Recent Patents on Perinatal Stem Cells

Contact Info

Product

Resources

About